Herald Sun










Link: [Subscription required]

British Journal of Cancer


In Australia, more money is spent on skin cancer than any other malignancy. Despite this, the mortality rate of melanoma, the deadliest form, has steadily increased over the past 50 years. Diagnostic imprecision and a lack of complementary molecular biomarkers are partially responsible for this lack of progress.


Whole-microRNAome profiling was performed on plasma samples from 32 patients with histologically confirmed melanoma and 16 normal controls. A classification algorithm was trained on these data and independently validated on multiple previously published microRNA data sets, representing (i) melanoma patient- and normal-blood, (ii) melanoma and nevi biopsy tissue, and (iii) cell lines and purified exosomes.


38 circulating microRNAs had biologically and statistically significant differences between melanoma and normal plasma samples (MEL38). A support vector machine algorithm, trained on these markers, showed strong independent classification accuracy (AUC 0.79–0.94). A majority of MEL38 genes have been previously associated with melanoma and are known regulators of angiogenesis, metastasis, tumour suppression, and treatment resistance.


MEL38 exhibits disease state specificity and robustness to platform and specimen-type variation. It has potential to become an objective diagnostic biomarker and improve the precision and accuracy of melanoma detection and monitoring. 


Healthcare IT News

Healthcare IT News Australia is the authoritative source on the people, policies and technologies driving next generation healthcare, delivering editorial insights into a tech frontier that is revolutionising patient care.


> Full story: Healthcare IT News

Melbourne Health Accelerator (MHx) Spring Cohort Presentation

Geneseq Biosciences presented the following poster and presentation at the final meeting of the Melbourne Health Accelerator program in December 2017.

World Melanoma Congress 2017

Geneseq Biosciences will be presenting the results of their Melaseq development activities at the World Melanoma Congress, being held in Brisbane, Australia in October 2017.